24th Aug 2020 16:31
Tissue Regenix Group PLC - medical devices company- Enters into a distribution agreement and secures first order with a speciality supplier of orthopaedic and biologic products, for the UK distribution of OrthoPure XT, following its recent CE Mark approval in June. OrthoPure XT is used for the reconstruction of knee ligaments to restore knee function and stability. Under the UK distribution agreement, the National Health Service and private healthcare sectors will have access to OrthoPure XT. Expects demand for OrthoPure XT to increase in 2021 as additional distribution opportunities are identified.
Current share price: 0.33 pence
Year-to-date change: down 67%
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group